A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of a Single Dose of Lanadelumab Administered Subcutaneously in Healthy Adult Japanese Subjects and Matched Healthy Adult Caucasian Subjects

Next Previous
Trial Profile

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of a Single Dose of Lanadelumab Administered Subcutaneously in Healthy Adult Japanese Subjects and Matched Healthy Adult Caucasian Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Lanadelumab (Primary)
  • Indications Diabetic macular oedema; Hereditary angioedema
  • Focus Pharmacokinetics
  • Sponsors Shire

    • Most Recent Events

    • 22 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 26 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 19 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top